• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • About
  • Contact Us
WeedWeek

WeedWeek

WeedWeek is the best way to keep up with the green rush

  • Membership
  • My Account
  • LinkedIn
  • Instagram
  • Twitter
  • Politics
  • Money
  • Ops
  • Brands
  • Culture
  • Events

EAZE, MEDMEN TRY TO REBOOT

By Alex Halperin
03/02/2020 06:20 AM GMT-0700
FacebookTweetPin

Struggling west coast giants Eaze and MedMen discussed their plans to rebuild. They are two of the best known brands in California, if not the country.

  • Eaze said it had raised $35M to pivot from being a delivery technology company to a plant-touching retailer. The company says it has 600,000 registered customers. “Verticalization is Eaze’s second act,” CEO Ro Choy said. Tech Crunch
  • The company raised a *$15M bridge investment from existing investors Rose Capital and DCM and an additional $20M led by an entity called FoundersJT. (An Eaze spokesperson declined to say more about that backer.) The company didn’t disclose the valuation.
  • Despite many publicized difficulties, Eaze’s business appears to be growing.
  • On LinkedIn, attorney David Feder expressed skepticism about Eaze’s plan. In the post, he imagines a conversation between a dispensary and Eaze:

“Dispensary: “Wait, but aren’t you my competitor, selling your own cannabis products directly to customers? Why should I give you MY customer’s name, contact info, location, basket sizes, shopping preferences and habits?”

“Eaze: “No no no. We’re totally not trying to sell OUR cannabis products to YOUR customers. Trust us. We only want to sell our cannabis to other people’s customers. Not yours. Basically, to everyone else except your customers.”

 

[gravityform id="5" title="true" description="false" ajax="true" tabindex=""]

On MedMen’s quarterly earnings call, the retailer discussed its “retail-first” turnaround plan.
CNN

  • “We cannot continue to invest in assets that are not producing near-term cash returns,” said Zeeshan Hyder, MedMen’s CFO.
  • The company reported 2Q revenue of $44.1M, up 50% from a year earlier and a net loss of $40.6M, up from $18.7M.
  • As of Sunday, the stock was priced at 24 cents/share.
  • In a bearish analysis, investment site Grizzle says the company “remains in a liquidity crisis.”

 

Quick Hit

  1. Entrepreneur Roger Obando, who lived through the dot-com crash, asked ‘What will happen to green rush victims?’ He recently appeared on the WeedWeek Podcast.
    Green Entrepreneur

Related

weedweek
Investing & Capital

WeedWeek acquired: Newsletter 10/16/25

Share:
FacebookTweetPin
Filed Under:
Investing & Capital

Primary Sidebar

Upcoming Webinar

Growth States

Growth States in 2025 & Beyond

Duration 60 minutes
Speakers Hirsh Jain, Alex Halperin

RSVP Here

Join WeedWeek California Pro Today!

WeedWeek Pro is the essential news and information resource for California cannabis professionals.

  • Access the Weedweek California Pro Newsletter
  • Access the California Tax and License Maps
  • Steep discounts on job posts in the WeedWeek career center
Sign Up

Get a risk-free 14 day trial for FREE!

Most Read

  • Regulation & Compliance

    EXCLUSIVE: We tested top Calif. prerolls for potency inflation

  • Regulation & Compliance

    Exclusive: Does Stiiizy have a diiiversiiion problem?

  • Industry Voices

    Calif. interstate commerce law opens pathway for licensed operators

Related Articles

See More Investing & Capital Articles
Investing & Capital

Who will back Pelorus’s $1B “roll up”?

dcc
Investing & Capital

SCOOP: Catalyst slams DCC ahead of diversion trial

What happened to Statehouse?
Investing & Capital

What happened to Statehouse?

Become a member and get access to exclusive content.

Join Now!

Footer

Join WeedWeek Pro

Become A Member Today and Get Access to Exclusive Content. Join here

Follow us

Follow WeedWeek for more content.

  • Instagram
  • LinkedIn
  • Twitter
  • About
  • Privacy Policy
  • Terms & Conditions
  • Contact
  • Advertise

RegStream Media Group © 2025. All Rights Reserved